CLINICAL TRIALS PROFILE FOR ETONOGESTREL

All Clinical Trials for ETONOGESTREL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00369967 ↗	Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents	Terminated	American College of Obstetricians and Gynecologists	N/A	2007-02-01	We hypothesize that using "quick start" initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start. We will conduct a randomized controlled trial comparing "quick start" to traditional start initiation of the contraceptive vaginal ring in adolescents seeking birth control. The primary study outcome is method continuation at 3, 6, and 12 months. Secondary outcomes include abnormal bleeding, product satisfaction, and adverse events.
NCT00369967 ↗	Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents	Terminated	Bayer	N/A	2007-02-01	We hypothesize that using "quick start" initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start. We will conduct a randomized controlled trial comparing "quick start" to traditional start initiation of the contraceptive vaginal ring in adolescents seeking birth control. The primary study outcome is method continuation at 3, 6, and 12 months. Secondary outcomes include abnormal bleeding, product satisfaction, and adverse events.
NCT00369967 ↗	Quick Start Initiation of the Contraceptive Vaginal Ring in Adolescents	Terminated	Virginia Commonwealth University	N/A	2007-02-01	We hypothesize that using "quick start" initiation of the contraceptive vaginal ring in adolescents seeking birth control will improve compliance compared to traditional start. We will conduct a randomized controlled trial comparing "quick start" to traditional start initiation of the contraceptive vaginal ring in adolescents seeking birth control. The primary study outcome is method continuation at 3, 6, and 12 months. Secondary outcomes include abnormal bleeding, product satisfaction, and adverse events.
NCT00403793 ↗	Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)	Completed	Bayer	Phase 2	2003-10-01	Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production after end of treatment.
NCT00403793 ↗	Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2003-10-01	Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production after end of treatment.
NCT00612508 ↗	Hormonal Contraception and Vaginal Health	Completed	Oregon Clinical and Translational Research Institute	N/A	2007-05-01	The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. The investigators plan to compare an oral route (taking birth control pills) with a vaginal route (using a vaginal ring).

Clinical Trial Conditions for ETONOGESTREL

Condition Name

Condition Name for ETONOGESTREL
Intervention	Trials
Contraception	35
HIV	5
Bleeding	4
Breakthrough Bleeding	3

Condition MeSH

Condition MeSH for ETONOGESTREL
Intervention	Trials
Hemorrhage	12
Uterine Hemorrhage	8
Dysmenorrhea	4
HIV Infections	3

Clinical Trial Locations for ETONOGESTREL

Trials by Country

Trials by Country for ETONOGESTREL
Location	Trials
United States	82
Brazil	9
Peru	3
South Africa	3
Thailand	3

Trials by US State

Trials by US State for ETONOGESTREL
Location	Trials
Colorado	10
Oregon	7
Utah	5
Virginia	5
North Carolina	4

Clinical Trial Progress for ETONOGESTREL

Clinical Trial Phase

Clinical Trial Phase for ETONOGESTREL
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	1
Phase 4	32

Clinical Trial Status

Clinical Trial Status for ETONOGESTREL
Clinical Trial Phase	Trials
Completed	33
Recruiting	12
Not yet recruiting	11

Clinical Trial Sponsors for ETONOGESTREL

Sponsor Name

Sponsor Name for ETONOGESTREL
Sponsor	Trials
Merck Sharp & Dohme Corp.	20
University of Colorado, Denver	7
Oregon Health and Science University	6

Sponsor Type

Sponsor Type for ETONOGESTREL
Sponsor	Trials
Other	91
Industry	29
NIH	7

ETONOGESTREL Market Analysis and Financial Projection

Last updated: February 4, 2026

What is the current status of clinical trials for etonogestrel?

Etonogestrel, a synthetic progestin, is primarily used in contraceptive products such as implants and vaginal rings. As of 2023, efforts to expand its indications and formulations are ongoing, but no new large-scale clinical trials targeting novel indications have been registered recently in major databases like ClinicalTrials.gov.

Phase and Types of Trials

• Contraceptive Implants: Classified as already FDA-approved (e.g., Nexplanon), with continuous trials focusing on device safety, efficacy, and user experience.
• Vaginal Ring Formulations: Existing products like NuvaRing utilize etonogestrel, with ongoing post-market surveillance studies.
• New Indications: Trials investigating ectopic pregnancy prevention and management, hormone replacement therapy, or contraceptive efficacy in specific populations are either in early stages or pending approval.

Clinical trial landscape

• No publicly registered trials for etonogestrel as a standalone drug candidate seeking regulatory approval for novel indications in the recent year.
• Most ongoing studies address device delivery mechanisms rather than the molecule itself.

How does the market for etonogestrel-based products look currently?

Market size and segmentation

• The global contraceptive market was valued at approximately $22 billion in 2022, projected to reach $29 billion by 2027, at a CAGR of 5.6%.[1]
• Etonogestrel-based products, primarily implants and vaginal rings, represent about 12-15% of this market segment.
• Leading products include Nexplanon (Merck), Implanon (historical), and NuvaRing (Merck).

Key players

• Merck: Dominates the market with Nexplanon. Holds approximately 60% market share for etonogestrel-based contraceptive devices.
• Other Manufacturers: Coopersurgical, Bayer, and private-label producers operate in emerging markets, often offering generic or locally approved combinations.

Market dynamics

• Rising demand in emerging markets due to increased contraceptive awareness.
• Growing preference for long-acting reversible contraceptives (LARCs), which favor implantable devices like etonogestrel implants.
• Patent expirations of earlier-generation devices lead to increased generic competition.

What are the market projections for etonogestrel products?

Short-term outlook (2023–2027)

• The market is expected to grow steadily, driven by increased acceptance of LARCs.
• Launch of new formulations, including biodegradable implants and novel delivery systems, could expand the market.
• Regulatory approvals for extended indications could open new revenue streams, especially for hormonal contraceptives in specific populations.

Long-term outlook (2028–2033)

• Market expansion will depend on:
  • Development of new indications: hormone replacement therapy, emergency contraception.
  • Patient preference shifts toward non-invasive options.
  • Regulatory approval of biosimilar and generic products reducing costs.
• Innovation in bioadhesive or biodegradable implants might reshape product offerings.

Regional insights

• North America and Europe dominate current markets, with high contraceptive adoption rates.
• Rapid growth expected in Southeast Asia, Sub-Saharan Africa, and Latin America due to increasing healthcare access and contraceptive awareness.

What are the regulatory and scientific challenges?

• Regulatory hurdles: Approval processes for new indications remain lengthy, requiring comprehensive safety and efficacy data.
• Scientific challenges: Addressing implant removal ease, minimizing adverse effects like irregular bleeding, and developing biodegradable formulations.
• Market access: Cost barriers and policy restrictions in certain regions limit product penetration.

Key Takeaways

• No recent large-scale clinical trials for etonogestrel as a novel drug candidate; focus remains on device-based delivery.
• The market for etonogestrel (implant and ring) is mature in developed regions, with growth driven by demand for long-acting contraceptives.
• Emerging markets exhibit significant growth potential due to increased contraceptive adoption.
• Future expansion depends on regulatory approvals for additional indications and technological advances in delivery systems.
• Competitive landscape is dominated by Merck, with increasing generic options reducing costs and expanding access.

FAQs

1. Are there any new formulations of etonogestrel in development?
Research focuses on biodegradable implants and improved delivery systems, but no new formulations have received regulatory approval or entered late-stage clinical trials as of 2023.

2. What is the primary indication for etonogestrel currently?
Contraception, primarily in implant form (e.g., Nexplanon) and vaginal rings (e.g., NuvaRing).

3. What challenges does the industry face concerning etonogestrel?
Regulatory hurdles for new indications, patient acceptance of delivery devices, and competition from generics.

4. How does regional variation impact market growth?
Developed regions have high adoption rates, while emerging markets are expanding rapidly due to increasing awareness and healthcare access.

5. Will new clinical trials influence the market?
Yes, particularly if they demonstrate additional indications or improved delivery systems that address current limitations.

---

References

[1] Market Data Forecasters, "Global Contraceptive Market Outlook," 2022.